MLTX
MoonLake Immunotherapeutics (NASDAQ)
Healthcare — Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Buy
1.9 / 5
13 analysts
$19.12
$-0.94 (-4.69%)
Target:
$28.00
(46.4%)
Sign in to add MLTX to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $1.60B |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.58 |
| EPS (TTM) | $-3.88 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -77.85% |
| Debt/Equity | 39.68 |
| Recommendation | Buy 1.9 |
| Analyst Target | $28.00 |
| Analysts | 13 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 60.1 |
| Beta | 1.04 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $62.75 |
| 52-Week Low | $5.95 |
| 50-Day Avg | $18.20 |
| 200-Day Avg | $17.34 |
| Avg Volume | $1.10M |
| Volume | 523.8K |
Performance Analysis
BULLISHMLTX shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 23% of its 52-week range.
+
RSI at 60.1 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Buy" from 13 analysts.
+
Average analyst target of $28.00 implies 46.4% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:20 UTC
Back to Screener Export Report